Table 1 Basic characteristics of NK-1RAs in FAERS.

From: Analyzing the adverse events of NK-1 receptor antagonists: a pharmacovigilance study from the FAERS database

Categories

APR, %

FAP, %

RP, %

Cases

3596

989

849

Gender

   

Female

1893 (52.6)

498 (50.4)

377 (44.4)

Male

1192 (33.1)

372 (37.6)

254 (29.9)

Missing

511 (14.2)

119 (12.0)

218 (25.7)

Age, years

   

< 18

98 (2.7)

20 (2.0)

1 (0.1)

18-64.9

1475 (41.0)

494 (49.9)

151 (17.8)

65–85

745 (20.7)

239 (24.2)

117 (13.8)

> 85

13 (0.4)

4 (0.4)

2 (0.2)

Missing

1265 (35.2)

232 (23.5)

578 (68.1)

Weight, kg

   

< 50

135 (3.8)

62 (6.3)

8 (0.9)

50–100

908 (25.3)

399 (40.3)

96 (11.3)

> 100

83 (2.3)

39 (3.9)

12 (1.4)

Reporters

   

Consumer

1075 (29.9)

193 (19.5)

400 (47.1)

Health Professional

129 (3.6)

52 (5.3)

16 (1.9)

Doctor

1051 (29.2)

421 (42.6)

97 (11.4)

Pharmacist

615 (17.1)

206 (20.8)

103 (12.1)

Others

673 (18.7)

102 (10.3)

230 (27.1)

Report countries

   

United States

1810 (50.3)

416 (42.0)

836 (98.5)

France

478 (13.3)

3 (0.3)

1 (0.1)

Korean

349 (9.7)

339 (34.3)

NA

Japan

294 (8.2)

125 (12.6)

NA

Serious outcomes

   

Death

338 (9.4)

65 (6.5)

250 (29.4)

Hospitalization-initial or prolonged

810 (22.5)

217 (21.9)

129 (15.1)

Life-threatening

214 (5.9)

63 (6.3)

10 (1.1)

Disability

35 (0.9)

9 (0.9)

0

Other serious outcomes

888 (24.7)

334 (33.8)

265 (22.8)